Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
CompletedNot applicableNCT04385030
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Traumatic injuries of the brachial plexus cause sufficient weakness to affect the individual in its various aspects, limiting the execution of Activities of Daily Living, leading to highly disabling, and often definitive, clinical conditions with serious socioeconomic consequences. It causes motor, sensory and autonomic deficits, directly compromising the quality of life and functional performance of these individuals. It is a complex condition, whose recovery is usually slow and costly, in addition to often requiring surgery and rehabilitation. Among the therapeutic possibilities, the non-invasive neuromodulation techniques stand out, especially the Transcranial Direct Current Stimulation (ETCC) and the Mirror Therapy (ET). In this context, the present study aims to analyze the effectiveness of the ETCC technique combined with ET in the treatment of patients with pain due to trauma to the brachial plexus, investigating the degree of improvement in pain intensity, functionality, quality of life and mood of these patients, comparing the onset with immediately after applying the techniques.
Study details
- Official title
- Transcranial Direct Current Stimulation and Mirror Therapy in Neuropathic Pain
- Conditions
- Interventions
- Device: TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY
- Sponsor
- Federal University of Paraíba
- Start date
- 2019-09-08
- Primary completion
- 2020-02-28
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Brazil
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age over 18 years; * Score of 4 to 10 points on the Visual Analogue Scale; * Persistent pain and refractory to clinical treatment for at least 3 months; * Appropriate pharmacological treatment for pain for at least 1 month before the start of the study. Exclusion Criteria: * Patients with other neurological diseases; * Past history of substance abuse; * Contraindications for ETCC.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04385030